
==== Front
BMC Neurol
BMC Neurol
BMC Neurology
1471-2377
BioMed Central London

2224
10.1186/s12883-021-02224-6
Research
BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage
Wang Wei 1
Wang Maode 1
Jiang Haitao 1
Wang Tuo 1
Da Rong da_rong@xjtu.edu.cn

2
1 grid.452438.c Department of Neurosurgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
2 grid.452438.c Department of Clinical Laboratory, The First Affiliated Hospital of Xi’an Jiaotong University, No.277 Yanta West Road, Xi’an, 710061 Shaanxi China
12 5 2021
12 5 2021
2021
21 1956 3 2021
5 5 2021
© The Author(s) 2021
https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

The effects of BRAFnon-V600E and BRAFV600E on the outcomes and the molecular characteristics of adult glioma patients are unknown and need to be explored, although BRAFV600E has been extensively studied in pediatric glioma.

Methods

Co-occurring mutations and copy number alterations of associated genes in the MAPK and p53 pathways were investigated using data from The Cancer Genome Atlas (TCGA) public database retrieved by cBioPortal. The prognosis of available adult glioma cohorts with BRAFV600E and BRAFnon-V600E mutations were also investigated.

Results

Ninety patients with BRAFV600E or BRAFnon-V600E were enrolled in this study, and data from 52 nonredundant patients were investigated. Glioblastoma multiform was the most common cancer type, with BRAF non-V600E and BRAFV600E. TP53 (56.00% vs. 7.41%), IDH1/2 (36.00% vs. 3.70%), and ATRX (32.00% vs. 7.41%) exhibited more mutations in BRAFnon-V600E than in BRAFV600E, and TP53 was an independent risk factor (56.00% vs. 7.41%). Both BRAFnon-V600E and BRAFV600E frequently overlapped with CDKN2A/2B homozygous deletions (HDs), but there was no significant difference. Survival analysis showed no difference between the BRAF non-V600E and BRAFV600E cohorts, even after excluding the survival benefit of IDH1/2 mutations and considering the BRAFnon-V600E mutations in the glycine-rich loop (G-loop) and in the activation segment. The estimated mean survival of patients with BRAFnon-V600E & IDH1/2WT with mutations in the G-loop groups was the shortest.

Conclusions

BRAFnon-V600E exhibited a stronger association with IDH1/2 mutations than BRAFV600E, but no survival advantage was found.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12883-021-02224-6.

Keywords

Adult patient with glioma
BRAFnon-V600E
BRAFV600E
IDH1/2
issue-copyright-statement© The Author(s) 2021
==== Body
Background

BRAF (v-raf murine sarcoma viral oncogene homolog B1) is a serine-threonine kinase in the Ras/Raf/mitogen-activated protein kinase (MAPK) pathway [1, 2] that transduces mitogenic stimuli after the activation by growth factor receptors that are involved in cell survival, proliferation, and differentiation [3]. MAPK pathway activation is common in various neoplasms. Active RAS mutations have been detected in approximately 15% of malignant human tumors.

Compared with ARAF and RAF1, BRAF plays a critical role in kinase activity [4]. A previous study showed that RAF1 is activated by BRAF through direct interactions between proteins and phosphorylation [5]. BRAF participates in the pathological mechanism of 7% of human neoplasms, especially in patients with melanoma and colorectal, thyroid, and lung cancer [6, 7]. The expression of BRAF is highly restrained [1, 8]. The high expression of BRAF in neural cells indicates that it is a vital MEK kinase in neuronal tissues [9, 10]. BRAF mutations are found in some central nervous system neoplasms. In pediatric low-grade gliomas (LGGs), these alterations correlate with oncogenic senescence, which may contribute to an improved prognosis [11]. The BRAFV600E mutation is rare in adult LGGs and glioblastomas and can only be found in 1 to 5% of samples [12, 13]. While BRAF activation contributes to tumor development and progression in the neural stem cells and progenitor cells of Homo sapiens, BRAF mutations are detected in adult diffuse gliomas and are associated with poor outcomes [14].

Most studies have focused on the BRAFV600E mutation, although more than 70 BRAF mutations have been reported to date. Mutations in BRAF at V600 can activate ERK, which plays a critical role in the G1/S transition by adjusting the expression of cyclin D, cyclin E, and p21Cip1 [15]. The BRAFV600E mutation is the most potent MAPK pathway activator, whereas BRAFnon-V600E mutations are low-activity kinases that slightly stimulate the MAPK pathway [16]. However, these low-activity BRAF mutants could activate MAPK signaling in COS-1 cells to a high level by activating RAF1 [16].

Isocitrate dehydrogenase (IDH) is a frequent mutation associated with a survival benefit in glioma patients and it has been defined as a molecular parameter to define the categories of brain tumors in the updated 2016 edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) [17]. IDH1 and BRAFV600E mutations are associated with infiltrative gliomas or circumscribed gliomas and glioneuronal tumors, respectively [18, 19], and they are exclusive in most cases [20]. The exact effect of BRAF non-V600E and BRAFV600E on the prognosis of glioma patients and whether there are unique molecular characteristics in their MAPK and p53 pathways remain largely unknown.

In this study, co-occurring mutations and copy number alterations of 35 associated genes in the MAPK and p53 pathways were retrieved and investigated, and the prognosis of the available adult glioma cohorts with BRAFV600E and BRAFnon-V600E were evaluated by using The Cancer Genome Atlas (TCGA) public database. We determined that BRAFnon-V600E exhibited a stronger association with the IDH1/2 mutation than BRAFV600E, but no survival advantage was found.

Methods

Data collection and enrollment

All data were collected and generated from the TCGA public database using the TCGA data mining tool cBioPortal (https://www.cbioportal.org/) [21, 22]. We strictly followed the TCGA publication guidelines (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/using-tcga/citing-tcga). In multiple patient cohorts of all twenty available CNS/brain studies (6164 samples), the available data were queried, including the gene mutations, copy number alterations, mRNA expression, and protein expression data of patients with BRAF gene mutations. In each study, the mutations were selected for genomic profiles. Samples with mutation data were selected for the patient/case set and entered into three groups: (1) General: Ras-Raf-MEK-ErK/JNK signaling (26 genes), including KRAS, HRAS, BRAF, RAF1, MAP 3 K1, MAP 3 K2, MAP 3 K3, MAP 3 K4, MAP 3 K5, MAP 2 K1, MAP 2 K2, MAP 2 K3, MAP 2 K4, MAP 2 K5, MAPK1, MAPK3, MAPK4, MAPK6, MAPK7, MAPK8, MAPK9, MAPK12, MAPK14, DAB2, RASSF1, and RAB25; (2) General: p53 signaling (6 genes), including TP53, MDM2, MDM4, CDKN2A, CDKN2B, and TP53BP1; (3) Other frequently mutated genes, including IDH1, IDH2, and ATRX, were then submitted for query. Among the downloadable data files, the available data regarding the mutations, copy number alterations, mRNA expression, and protein expression were downloaded. In the type of genetic alterations across all samples, samples harboring the BRAF mutation were chosen. Data regarding mutations and copy number alterations on the summary page and the patient and sample data on the clinical data page were downloaded. All of the data were recorded in a chart for further analysis (Supplementary Dataset S1).

Major characteristics of the BRAFV600E and BRAFnon-V600E cohorts using univariate logistic regression analysis

The enrolled populations were divided into BRAFV600E and BRAFnon-V600E groups. The numbers and percentages of categorical variables were calculated. Their demographic characteristics, including sex, diagnosis age, cancer type, and overall survival status, were analyzed using univariate logistic regression analysis. The odds ratios (ORs) and 95% confidence intervals (CIs) were estimated.

Co-occurring mutations of the BRAFV600E and BRAFnon-V600E cohorts using univariate and multivariate logistic regression analysis

The numbers and percentages of categorical variables were calculated in the BRAFV600E and BRAFnon-V600E groups. The available data for co-occurring mutated genes in these two groups were analyzed using univariate logistic regression analysis. Thereafter, significant variables (P < 0.10) were analyzed using multivariate logistic regression analysis. The ORs and 95% CIs were estimated.

Co-occurring copy number alterations in the BRAFV600E and BRAFnon-V600E cohorts using heatmap and univariate logistic regression analysis

The available copy number alterations of the BRAFV600E and BRAFnon-V600E cohorts were retrieved and displayed using a heatmap by Morpheus (https://software.broadinstitute.org/morpheus). The putative copy-number alterations are as follows: − 2 = homozygous deletion; − 1 = hemizygous deletion; 0 = neutral/no change; 1 = gain; 2 = high-level amplification. Univariate logistic regression analysis was used to calculate the numbers and percentages of CDKN2A homozygous deletion (HD) and CDKN2B HD. The ORs and 95% CIs were estimated.

Crossover analysis with Kaplan–Meier survival curves and the log rank (mantel-Cox) test

The overall survival rates of the BRAFV600E and BRAFnon-V600E cohorts were compared using Kaplan-Meier curves and the log rank (Mantel-Cox) test [23]. To exclude the benefit of IDH1/2 on survival, we referred to the BRAFV600E & IDH1/2WT group as the BRAFV600E group minus those with IDH1/2 mutations, as well the BRAF non-V600E & IDH1/2WT group as the BRAF non-V600E group minus those with IDH1/2 mutations. The survival of the BRAFV600E & IDH1/2WT group was compared with that of the BRAFnon-V600E & IDH1/2WT groups. There were two clusters of mutations, one in the glycine-rich loop (referred to as the G-loop) and the other in the activation segment. To evaluate the effect of the mutation site on survival, we defined two subgroups in the BRAFnon-V600E & IDH1/2WT group. One subgroup was the BRAFnon-V600E & IDH1/2WT group with the mutation site in the G-loop, and the other subgroup was the BRAFnon-V600E & IDH1/2WT group with the mutation site in the activation segment. The BRAFV600E & IDH1/2WT group was compared with those two subgroups. Furthermore, the G-loop BRAFnon-V600E & IDH1/2WT subgroup was compared with the remaining patients in the BRAFnon-V600E & IDH1/2WT group.

Statistical analysis

Major characteristics, co-occurring mutations and copy number alterations of the BRAFV600E and BRAFnon-V600E cohorts were analyzed using univariate logistic regression analysis. Significant variables (P < 0.10) of co-occurring mutations of the BRAFV600E and BRAFnon-V600E cohorts were analyzed using multivariate logistic regression analysis. Kaplan-Meier curves were generated for glioma patients with BRAF mutations and were compared using the log-rank (Mantel-Cox) test. A P value < 0.05 was considered statistically significant.

Results

Data enrollment in the study

In all 20 CNS/brain studies (6164 samples), 4674 samples with mutation data were queried; 90 samples (90 patients) with BRAF mutations, including 53 samples (53 patients) with BRAFV600E and 37 samples (37 patients) with BRAFnon-V600E, are shown in Table 1. The cancer types of 20 CNS/brain studies included diffuse glioma, glioblastoma, oligodendroglioma, embryonal tumor, encapsulated glioma, and miscellaneous neuroepithelial tumor. The scheme for the final enrolled and investigated data is shown in Fig. 1. Ninety patients with BRAFV600E or BRAFnon-V600E were enrolled in this study, and data from 52 nonredundant patients were investigated. The integrated data of their major patient characteristics, including sex, age, diagnosis age, cancer type, data of co-occurring mutations, copy number alterations, and overall survival time and status, were collected for further analysis. Table 1 The CNS/brain projects of TCGA database enrolled in the study retrieved by cBioPortal

Project	All Samples	Samples with mutation data	Samples with BRAFV600E	Samples with BRAFnon-V600E	References	
Diffuse Glioma	
 Brain Lower Grade Glioma (TCGA, Firehose Legacy)	530	286	1	1	https://www.cancer.gov	
 Brain Lower Grade Glioma (TCGA, PanCancer Atlas)	514	512	1	2	[24–29]	
 Glioma (MSK, Nature 2019)	91	91	2	1	https://www.cancer.gov	
 Glioma (MSKCC, Clin Cancer Res 2019)	1004	1004	22	19	[30]	
 Low-Grade Gliomas (UCSF, Science 2014)	61	61	2	0	[31]	
 Merged Cohort of LGG and GBM (TCGA, Cell 2016)	1102	812	5	2	[32]	
GLIOBLASTOMA	
 Brain Tumor PDXs (Mayo Clinic, 2019)	95	83	2	1	https://www.cbioportal.org	
 Glioblastoma (Columbia, Nat Med. 2019)	42	32	1	1	[33]	
 Glioblastoma (TCGA, Cell 2013)	543	257	3	0	[34]	
 Glioblastoma (TCGA, Nature 2008)	206	91	0	0	[35]	
 Glioblastoma Multiforme (TCGA, Firehose Legacy)	604	290	5	1	https://www.cancer.gov	
 Glioblastoma Multiforme (TCGA, PanCancer Atlas)	592	397	5	3	[24–29, 36]	
OLIGODENDROGLIOMA	
 Anaplastic Oligodendroglioma and Anaplastic Oligogastrocytoma (MSKCC, Neuro Oncol 2017)	22	22	0	0	[37]	
Embryonal Tumor	
 MEDULLOBLASTOMA	
  Medulloblastoma (Broad, Nature 2012)	92	92	0	0	[38]	
  Medulloblastoma (ICGC, Nature 2012)	125	125	0	0	[39]	
  Medulloblastoma (PCGP, Nature 2012)	37	37	0	0	[40]	
  Medulloblastoma (Sickkids, Nature 2016)	46	46	0	1	[41]	
Encaspulated Glioma	
 PILOCYTIC ASTROCYTOMA	
  Pilocytic Astrocytoma (ICGC, Nature Genetics 2013)	96	96	4	3	[42]	
Miscellaneous Neuroepithelial Tumor	
 Pheochromocytoma and Paraganglioma (TCGA, Cell 2017)	178	178	0	1	[43]	
 Pheochromocytoma and Paraganglioma (TCGA, Firehose Legacy)	184	162	0	1	https://www.cancer.gov	

Fig. 1 The scheme of the enrollment and investigation of data. In all 20 CNS/Brain studies, including 6164 samples, 90 patients with BRAFV600E or BRAFnon-V600E were enrolled; 52 nonredundant patients displayed major patient characteristics, including sex, age, cancer type detailed, co-occurring mutations, and copy number alteration genes, and were enrolled for further analysis

Major characteristics of the cohorts with BRAFV600E and BRAFnon-V600E

The study populations were divided into two groups, BRAFV600E and BRAFnon-V600E. The major demographic characteristics and clinical data of the two groups are summarized in Table 2. The patients’ ages ranged from 20 to 85 years and were divided into early adulthood, midlife, mature adulthood, and late adulthood (aged 20–35, 35–50, 50–80, and > 80 years, respectively). The two groups had comparable proportions of male patients, diagnosis age, cancer type, and overall survival status. Glioblastoma multiform was the most common cancer type in both cohorts (74.07% vs. 56.00%; P = 0.175; Table 2). Table 2 The major characteristics of cohorts including BRAFV600E and BRAFnon-V600E

Variables	BRAFV600E
(n = 27)	BRAFnon-V600E
(n = 25)	Univariate analysis	
Number	%	Number	%	Odds Ratio	95% Confidence Interval	P Value	
Male	16	59.26	18	72.00	0.566	0.177–1.809	0.337	
Diagnosis Age	
 Ages 20–35	9	33.33	6	24.00	1.583	0.469–5.350	0.459	
 Ages 36–50	9	33.33	8	32.00	1.062	0.333–3.390	0.918	
 Ages 51–80	7	25.93	11	44.00	0.445	0.139–1.433	0.175	
 Age 80+	2	7.41	0	0.00	1,615,474,843	0.000-	0.999	
Cancer type detailed	
 Glioblastoma Multiform	20	74.07	14	56.00	2.245	0.698–7.219	0.175	
 Astrocytoma	3	11.11	6	24.00	0.396	0.087–1.794	0.229	
 Oligoastrocytoma	1	3.70	0	0.00	1,553,341,195	0.000-	1.000	
 Oligodendroglioma	0	0.00	3	12.00	0.000	0.000-	0.999	
 Gliosarcoma	0	0.00	2	8.00	0.000	0.000-	0.999	
 Other glioma	3	11.11	0	0.00	1,682,786,295	0.000-	0.999	
Overall survival status	
 Deceased	14	51.85	11	44.00	1.371	0.460–4.087	0.572	

Co-occurring mutations of the BRAFV600E and BRAFnon-V600E cohorts using univariate and multivariate logistic regression analysis

Available co-occurring gene mutations of the BRAFV600E and BRAFnon-V600E cohorts were retrieved, and differences between the two groups were compared; the results are summarized in Table 3. The mutation frequencies of KRAS, HRAS, RAF1, MAP 3 K1, MAP 2 K1, MAP 2 K2, MAP 2 K4, MDM2, MDM4, CDKN2A, and CDKN2B were comparable between the two groups. In contrast, the BRAFnon-V600E group exhibited a significantly higher mutation frequency of TP53 (56.00% vs. 7.41%; P = 0.001), IDH1/2 (36.00% vs. 3.70%; P = 0.015), and ATRX (32.00% vs. 7.41%; P = 0.037) than the BRAFV600E group. The variables with P < 0.10 were analyzed using multivariate logistic regression analysis, and the BRAFnon-V600E group exhibited a significantly higher TP53 mutation frequency (56.00% vs. 7.41%; P = 0.031) than the BRAFV600E group (Table 3). Table 3 The co-occurred mutations of BRAFV600E and BRAFnon-V600E cohort using univariate and multivariate logistics regression analysis

Gene	BRAFV600E
(n = 27)	BRAFnon-V600E
(n = 25)	Univariate analysis	Multivariate analysis	
Number	%	Number	%	Odds Ratio	95% Confidence Interval	P Value	Odds Ratio	95% Confidence Interval	P Value	
KRAS	0	0.00	1	4.00	1,817,409,198	0.000-	1.000				
HRAS	0	0.00	1	4.00	1,817,409,198	0.000-	1.000				
RAF1	0	0.00	2	8.00	1,896,426,989	0.000-	0.999				
MAP 3 K1	1	3.70	6	24.00	8.211	0.911–73.959	0.060				
MAP 2 K1	0	0.00	2	8.00	1,896,426,989	0.000-	0.999				
MAP 2 K2	0	0.00	4	16.00	2,077,039,084	0.000-	0.999				
MAP 2 K4	0	0.00	2	8.00	1,896,426,989	0.000-	0.999				
TP53	2	7.41	14	56.00	15.909	3.078–82.224	0.001	12.186	1.251–118.721	0.031	
MDM2	1	3.70	3	12.00	3.545	0.344–36.561	0.298				
MDM4	0	0.00	4	16.00	2,077,039,084	0.000-	0.999				
CDKN2A	0	0.00	3	12.00	1,982,628,216	0.000-	0.999				
CDKN2B	0	0.00	1	4.00	1,817,409,198	0.000-	1.000				
IDH1/2	1	3.70	9	36.00	14.625	1.690–126.537	0.015	5.498	0.512–59.020	0.159	
ATRX	2	7.41	8	32.00	5.882	1.110–31.170	0.037	0.665	0.048–9.188	0.761	

Co-occurring copy number alteration in the BRAFV600E and BRAFnon-V600E cohorts using heatmap and univariate logistic regression analysis

There were no available copy number data for five patients with BRAFV600E and five patients with BRAFnon-V600E. The copy number alterations of the available co-occurring genes included BRAF, RAF1, MAP 3 K1, MAP 2 K1, MAP 2 K2, MAP 2 K4, MAPK1, MAPK3, TP53, MDM2, MDM4, TP53BP1, IDH1, IDH2, ATRX, CDKN2A, and CDKN2B. The HD copy number was frequently retrieved for these two genes, including CDKN2A and CDKN2B (Fig. 2), and the HD of both CDKN2A (77.27.00% vs. 60.00%; P = 0.032) and CDKN2B (77.27.00% vs. 60.00%; P = 0.032) was more frequent in the BRAFV600E cohort than in the BRAFnon-V600E cohort (Table 4). Fig. 2 The co-occurring copy number alterations of the BRAFV600E cohort and BRAFnon-V600E cohort using a heatmap. The cohorts of BRAFV600E (red) or BRAFnon-V600E (green) are shown, and putative copy-number alterations change from light to dark with value enhancement

Table 4 CDKN2A/2B HD of BRAFV600E and BRAFnon-V600E cohort using univariate logistics regression analysis

Variables	BRAFV600E
(n = 22)	BRAFnon-V600E
(n = 20)	Univariate analysis	
Number	%	Number	%	Odds Ratio	95% Confidence Interval	P Value	
CDKN2A	17	77.27	12	60.00	0.193	0.043–0.867	0.032	
CDKN2B	17	77.27	12	60.00	0.193	0.043–0.867	0.032	

Crossover analysis using Kaplan–Meier survival curves and the log-rank (mantel-Cox) test

Crossover Kaplan–Meier survival curves and the log-rank (Mantel-Cox) test were performed to explore the difference between the overall survival of glioma patients with BRAFV600E and BRAFnon-V600E. The estimated mean survival time was 51.394 months for patients with BRAFV600E, 89.958 months for patients with BRAFnon-V600E, 44.500 months for patients with BRAFV600E & IDH1/2WT, and 93.821 months for patients with BRAFnon-V600E & IDH1/2WT. There was no difference between the survival of BRAFV600E and BRAFnon-V600E (51.394 vs. 89.958, chi-square 1.130, P = 0.288). In addition, there was no difference between the survival of BRAFV600E & IDH1/2WT and BRAFnon-V600E & IDH1/2WT (44.500 vs. 93.821, chi-square 0.007, P = 0.935), which excluded the survival benefit of IDH1/2. We also evaluated the survival of BRAFnon-V600E & IDH1/2WT with mutations in the G-loop and activation segment. The estimated survival time of these two subgroups was 12.250 months for patients with BRAFnon-V600E & IDH1/2WT with mutations in the G-loop and 34.800 months for patients with BRAFnon-V600E & IDH1/2WT with mutations in the activation segment. In addition, there was no difference between the BRAFV600E & IDH1/2WT cohorts and those of the BRAFnon-V600E & IDH1/2WT cohorts. As shown below, BRAFV600E & IDH1/2WT vs. BRAFnon-V600E & IDH1/2WT had mutations in the G-loop (44.500 vs. 12.250, chi-squared 0.122, P = 0.727), and BRAFV600E & IDH1/2WT vs. BRAFnon-V600E & IDH1/2WT had mutations in the activation segment (44.500 vs. 34.800, chi-square 0.145, P = 0.703). Since the estimated mean survival of BRAFnon-V600E & IDH1/2WT with mutations in the G-loop was the shortest, we compared the BRAFnon-V600E & IDH1/2WT with mutations in the G-loop with the remaining BRAFnon-V600E & IDH1/2WT patients. There was no difference between them (12.250 vs. 95.100, chi-square 0.008, P = 0.927) (Fig. 3). The numbers at risk of Kaplan–Meier survival curves were shown in Supplementary Dataset S2. Fig. 3 Crossover analysis with Kaplan–Meier survival curves and the log-rank (Mantel-Cox) test. a BRAFV600E vs. BRAFnon-V600E (51.394 vs. 89.958, Chi-Square 1.130, P = 0.288); b BRAFV600E & IDH1/2WT vs. BRAFnon-V600E & IDH1/2WT (44.500 vs. 93.821, Chi-Square 0.007, P = 0.935); c BRAFV600E & IDH1/2WT vs. BRAFnon-V600E & IDH1/2WT with mutations in G-loop (44.500 vs. 12.250, Chi-Square 0.122, P = 0.727); d BRAFV600E & IDH1/2WT vs. BRAFnon-V600E & IDH1/2WT with mutations in activation segment (44.500 vs. 34.800, Chi-Square 0.145, P = 0.703); e BRAFnon-V600E & IDH1/2WT with mutations in G-loop vs. the rest BRAFnon-V600E & IDH1/2WT patients (12.250 vs. 95.100, Chi-Square 0.008, P = 0.927)

Discussion

BRAF mutations critically affect cancer growth and progression and are supposed to be a founder event for mutations occurring early in the initiation process of cancer. However, BRAF mutations must cooperate with other mechanisms for a fully cancerous state, as they are insufficient to induce cancer alone [5]. BRAFV600E has been the mutation of interest in previous studies on glioma, especially in pediatric glioma patients, for the available molecule-targeted drugs. However, various BRAFnon-V600E cells exert different activation effects on the MAPK pathway. The exact impact on the clinical prognosis and possible molecular mechanism of associated co-occurring genes with mutations or copy number alterations co-occurring with BRAF mutations remains unclear in adult glioma patients. In this study, the available data of patients with BRAFnon-V600E and BRAFV600E in the TCGA CNS/brain database were investigated to determine the possible mechanisms of BRAF gene mutations in adult glioma patients.

Our data indicated that in adult glioma patients with BRAF mutations, including both BRAFnon-V600E and BRAFV600E cohorts, glioblastoma multiform was the most common cancer type. A previous study showed that all BRAFV600E glioblastomas were primary tumors in both pediatric and adult patients [44]. Tabouret et al. [20] reported a case the co-occurrence of both IDH1 mutation and BRAFV600E although those two mutations are mutually exclusive in glial tumor. The available co-occurring mutated genes in the MAPK and p53 pathways showed that mutated genes frequently co-occurred in the BRAFnon-V600E cohort, and there were more TP53, IDH1/2, and ATRX mutations in BRAFnon-V600E than in BRAFV600E. Lai et al. [45] found that a TP53 point mutation at position 273 (Arg to Cys) was more common than IDH1 mutations at position 132 (Arg to His). They hypothesized that the TP53 mutation (C → T) occurred in the nontranscribed strand, while the IDH1 mutation existed in the transcribed strand, which is a strand asymmetry pattern [46]. Another study indicated that IDH1/2 mutations represent early events in brain tumor formation [47]. Liu et al. [48] found that ATRX alterations correlated with mutations in IDH1/2 and TP53 in glioma of all grades. It has been reported that ATRX deletions/mutations are correlated with TP53 and IDH1 mutations [49, 50]. Somatic TP53, ATRX, and IDH1/2 mutations have been found in adult LGGs [51]. ATRX mutations are detected in adult diffuse gliomas and astrocytomas harboring both TP53 and IDH1/2. The co-occurrence of these three mutated genes, including TP53, IDH1/2, and ATRX, facilitates the growth of an adult diffuse astrocytoma subgroup [48]. All of the studies above indicate that ATRX mutations frequently overlap with IDH1/2 and TP53 mutations. In the present study, we also found the co-occurrence of these three mutations, which were frequently detected in the BRAFnon-V600E cohort but not in the BRAFV600E cohort. Our findings indicated that in adult glioma patients, a possible correlation between BRAFnon-V600E and these three common mutations simultaneously occurred in glioma. Multivariate logistic regression revealed that TP53 was an independent risk factor in the BRAFnon-V600E cohort vs. the BRAFV600E group. Our data demonstrated a correlation between BRAFnon-V600E and TP53 mutations in adult glioma patients.

Previous findings have shown that active Ras can induce heterodimerization of BRAF and RAF1 [52] and that this event may be critical for RAF1 activation [53]. RAF1 directly regulates cell apoptosis, which does not depend on MAPK signaling [54, 55], but occurs through direct interaction with Bcl-2 [54]. TP53 can regulate Bcl-2 by suppressing Bcl-2 transcription [56]. We proposed that the BRAFnon-V600E mutation might activate the BRAF-RAF1 heterodimer, which shows antiapoptotic properties via the activation of Bcl-2 through RAF1 phosphorylation. Mutant TP53, which is frequently accompanied by IDH1/2 mutation by a strand asymmetry mechanism, fails to regulate Bcl-2. Therefore, with both activated RAF1 and mutated TP53, an enhanced antiapoptotic effect, which promotes cancer growth, might be predicted.

Compared to BRAF fusions, BRAFV600E tends to be more aggressive, more likely to be associated with CDKN2A/B deletions, and can transform cancers into higher-grade tumors [57, 58]. Our data showed that CDKN2A and CDKN2B HDs were more frequent in the BRAFV600E cohort than in the BRAFnon-V600E cohort. Concomitant CDKN2A and CDKN2B HDs could be detected in patients with glioblastoma multiform cancer, astrocytoma, and gliosarcoma. A previous report indicated that five of seven pediatric grade II–IV astrocytomas with BRAFV600E had concomitant CDKN2A HD [59] and CDKN2A deletions combined with BRAFV600E alterations, constituting a subgroup of secondary high-grade gliomas [60]. We found that in adult glioma patients, BRAFV600E and BRAFnon-V600E frequently co-occurred with CDKN2A HDs combined with CDKN2B HDs, especially in patients with BRAFV600E. Except for astrocytoma, glioblastoma multiform cancer was the most common cancer type with these combined alterations. Robinson et al. [61] indicated that activated Akt or Ink4a/ARF deletions are necessary for high-grade brain neoplasms with BRAF mutations in a Cre/lox animal model. Our results showed the possible synergy of CDKN2A and CDKN2B HDs with BRAF mutations, especially in adult glioma patients with BRAFV600E and BRAFnon-V600E.

BRAFV600E reportedly enhances BRAF kinase activity 500-fold [62]. According to its kinase viability, BRAFnon-V600E mutations can be classified into three groups: high activity (130–700 times), intermediate activity (1.3–64 times), and impaired activity (30–80%) [16]. Theoretically, the higher the BRAF kinase activity, the worse the prognosis. To clarify whether there is a difference between BRAFV600E and BRAFnon-V600E, we compared the overall survival of these two cohorts, and no statistical significance was found.

In addition, the status of IDH mutations in glioblastomas definitely influences the prognosis of patients with glioblastomas; therefore, IDH-wildtype glioblastomas are defined as primary tumors, while IDH-mutant glioblastomas are classified as secondary tumors [63]. To exclude the benefit of IDH mutations on survival, we compared the BRAFV600E & IDH1/2WT and BRAFnon-V600E & IDH1/2WT cohorts, and no difference was detected. The positions of the G-loop and the activation segment are 458–470 aa and 577–622 aa in BRAF, respectively [64]. Most BRAFnon-V600E mutations exist in the G-loop and the activation segment [16, 64]; therefore, we selected the two cohorts as BRAFnon-V600E & IDH1/2WT with mutations in the G-loop and activation segment. We compared them with BRAFV600E & IDH1/2WT, and no difference was found between the BRAFV600E & IDH1/2WT cohorts and those of the BRAFnon-V600E & IDH1/2WT cohorts. Furthermore, we compared BRAFnon-V600E & IDH1/2WT with mutations in the G-loop with the remaining BRAFnon-V600E & IDH1/2WT patients and found no difference between them. Although there was no statistical significance, the estimated mean survival of BRAFnon-V600E & IDH1/2WT with mutations in the G-loop was the shortest in all cohorts. We propose that a larger sample is necessary for confirmation of this finding. Our data indicated that the BRAFnon-V600E cohort had no survival advantage from co-occurrence with IDH mutations compared with the BRAFnon-V600E cohort of adult patients with glioma.

Limitations

Because the BRAFV600E mutation is rare in adult glioma, there were few patients in both cohorts retrieved from the publicly available data (cBioPortal). In this study, while their apparent survival times were substantially different, they were not significantly different. To prove the mechanism by which BRAF mutations promote cancer growth via an enhanced antiapoptotic effect of Bcl-2, further study using appropriate clinical tissue samples or animal models are necessary.

Conclusions

In conclusion, we found that in adult patients with gliomas, BRAFnon-V600E, rather than BRAFV600E, frequently co-occurs with TP53, IDH1/2, and ATRX mutations. Both BRAFnon-V600E and BRAFV600E frequently overlapped with CDKN2A/2B HDs, whereas there were no significant differences between the two cohorts. Although there were significant differences in co-occurring gene mutations and copy number alterations, no difference was found in survival between cohorts of BRAFnon-V600E and BRAFV600E with and without IDH1/2 favorable effects on survival. We also found that the estimated mean survival of BRAFnon-V600E & IDH1/2WT with mutations in the G-loop was the shortest; however, no difference was observed between that cohort and other cohorts. Due to the poor available mRNA and protein data in the TCGA database we retrieved in this study, no expression data were evaluated. More clinical data or models are necessary to elucidate the mechanism involved in BRAFnon-V600E-associated glioma in the future.

Supplementary Information

Additional file 1.

Additional file 2.

Abbreviations

HD Homozygous deletion

BRAF v-raf murine sarcoma viral oncogene homolog B1

LGGs Low-grade gliomas

TCGA The Cancer Genome Atlas

ORs Odds ratios

Cis Confidence intervals

G-loop Glycine-rich loop

MAPK Mitogen-activated protein kinase

Acknowledgements

The results published or shown here are in whole or part based upon public data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

Authors’ contributions

WW: Formal analysis, Writing- Original draft preparation. MW: Writing- Reviewing & Editing. HJ: Investigation. TW: Data curation. RD: Conceptualization, Methodology. All authors read and approved the final manuscript.

Funding

This study was financially supported by the Natural Science Basic Research Program of Shaanxi (Program No. 2018JM7062), and The Project of The First Affiliated Hospital of Xi’an Jiaotong University (XJYFY-2019w33).

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Mercer KE Pritchard CA Raf proteins and cancer: B-Raf is identified as a mutational target Biochim Biophys Acta 2003 1653 1 25 40 10.1016/s0304-419x(03)00016-7 12781369
2. Roskoski R Jr RAF protein-serine/threonine kinases: structure and regulation Biochem Biophys Res Commun 2010 399 3 313 317 10.1016/j.bbrc.2010.07.092 20674547
3. Basto D Trovisco V Lopes JM Martins A Pardal F Soares P Mutation analysis of B-RAF gene in human gliomas Acta Neuropathol 2005 109 2 207 210 10.1007/s00401-004-0936-x 15791479
4. Kaltsas P Want S Cohen J Development of a time-to-positivity assay as a tool in the antibiotic management of septic patients Clin Microbiol Infect 2005 11 2 109 114 10.1111/j.1469-0691.2004.01054.x 15679484
5. Dhomen N Marais R New insight into BRAF mutations in cancer Curr Opin Genet Dev 2007 17 1 31 39 10.1016/j.gde.2006.12.005 17208430
6. Network TCGAR Comprehensive molecular profiling of lung adenocarcinoma Nature. 2014 511 7511 543 550 10.1038/nature13385 25079552
7. Davies H Bignell GR Cox C Stephens P Edkins S Clegg S Teague J Woffendin H Garnett MJ Bottomley W Davis N Dicks E Ewing R Floyd Y Gray K Hall S Hawes R Hughes J Kosmidou V Menzies A Mould C Parker A Stevens C Watt S Hooper S Wilson R Jayatilake H Gusterson BA Cooper C Shipley J Hargrave D Pritchard-Jones K Maitland N Chenevix-Trench G Riggins GJ Bigner DD Palmieri G Cossu A Flanagan A Nicholson A Ho JWC Leung SY Yuen ST Weber BL Seigler HF Darrow TL Paterson H Marais R Marshall CJ Wooster R Stratton MR Futreal PA Mutations of the BRAF gene in human cancer Nature. 2002 417 6892 949 954 10.1038/nature00766 12068308
8. Barnier JV Papin C Eychene A Lecoq O Calothy G The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression J Biol Chem 1995 270 40 23381 23389 10.1074/jbc.270.40.23381 7559496
9. Catling AD Reuter CW Cox ME Parsons SJ Weber MJ Partial purification of a mitogen-activated protein kinase kinase activator from bovine brain. Identification as B-Raf or a B-Raf-associated activity J Biol Chem 1994 269 47 30014 30021 10.1016/S0021-9258(18)43982-8 7962002
10. Xie P Streu C Qin J Bregman H Pagano N Meggers E Marmorstein R The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase Biochemistry. 2009 48 23 5187 5198 10.1021/bi802067u 19371126
11. Raabe EH Lim KS Kim JM Meeker A Mao XG Nikkhah G Maciaczyk J Kahlert U Jain D Bar E Cohen KJ Eberhart CG BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model Clin Cancer Res 2011 17 11 3590 3599 10.1158/1078-0432.CCR-10-3349 21636552
12. Schindler G Capper D Meyer J Janzarik W Omran H Herold-Mende C Schmieder K Wesseling P Mawrin C Hasselblatt M Louis DN Korshunov A Pfister S Hartmann C Paulus W Reifenberger G von Deimling A Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma Acta Neuropathol 2011 121 3 397 405 10.1007/s00401-011-0802-6 21274720
13. Behling F Barrantes-Freer A Skardelly M Nieser M Christians A Stockhammer F Rohde V Tatagiba M Hartmann C Stadelmann C Schittenhelm J Frequency of BRAF V600E mutations in 969 central nervous system neoplasms Diagn Pathol 2016 11 1 55 10.1186/s13000-016-0506-2 27350555
14. Behling F Schittenhelm J Oncogenic BRAF alterations and their role in brain tumors Cancers (Basel) 2019 11 6 794 10.3390/cancers11060794
15. Woods D Parry D Cherwinski H Bosch E Lees E McMahon M Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1 Mol Cell Biol 1997 17 9 5598 5611 10.1128/MCB.17.9.5598 9271435
16. Wan PT Garnett MJ Roe SM Lee S Niculescu-Duvaz D Good VM Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell. 2004 116 6 855 867 10.1016/S0092-8674(04)00215-6 15035987
17. Komori T The 2016 WHO classification of Tumours of the central nervous system: the major points of revision Neurol Med Chir (Tokyo) 2017 57 7 301 311 10.2176/nmc.ra.2017-0010 28592714
18. Parsons DW Jones S Zhang X Lin JC Leary RJ Angenendt P An integrated genomic analysis of human glioblastoma multiforme Science. 2008 321 5897 1807 1812 10.1126/science.1164382 18772396
19. Zhang C Moore LM Li X Yung WK Zhang W IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma Neuro-Oncology 2013 15 9 1114 1126 10.1093/neuonc/not087 23877318
20. Tabouret E Fina F Vincentelli F Nanni I Figarella-Branger D New IDH1 I113T mutation associated with BRAF V600E mutation: new driver of gliomagenesis? J Neurol Sci 2014 342 1–2 204 206 10.1016/j.jns.2014.05.010 24857351
21. Cerami E Gao J Dogrusoz U Gross BE Sumer SO Aksoy BA Jacobsen A Byrne CJ Heuer ML Larsson E Antipin Y Reva B Goldberg AP Sander C Schultz N The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov 2012 2 5 401 404 10.1158/2159-8290.CD-12-0095 22588877
22. Gao J Aksoy BA Dogrusoz U Dresdner G Gross B Sumer SO Sun Y Jacobsen A Sinha R Larsson E Cerami E Sander C Schultz N Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci Signal 2013 6 269 pl1 10.1126/scisignal.2004088 23550210
23. Kleinbaum DG Klein M Kaplan–Meier Survival Curves and the Log–Rank Test 1996
24. Hoadley KA Yau C Hinoue T Wolf DM Lazar AJ Drill E Shen R Taylor AM Cherniack AD Thorsson V Akbani R Bowlby R Wong CK Wiznerowicz M Sanchez-Vega F Robertson AG Schneider BG Lawrence MS Noushmehr H Malta TM Stuart JM Benz CC Laird PW Caesar-Johnson SJ Demchok JA Felau I Kasapi M Ferguson ML Hutter CM Sofia HJ Tarnuzzer R Wang Z Yang L Zenklusen JC Zhang J(J) Chudamani S Liu J Lolla L Naresh R Pihl T Sun Q Wan Y Wu Y Cho J DeFreitas T Frazer S Gehlenborg N Getz G Heiman DI Kim J Lawrence MS Lin P Meier S Noble MS Saksena G Voet D Zhang H Bernard B Chambwe N Dhankani V Knijnenburg T Kramer R Leinonen K Liu Y Miller M Reynolds S Shmulevich I Thorsson V Zhang W Akbani R Broom BM Hegde AM Ju Z Kanchi RS Korkut A Li J Liang H Ling S Liu W Lu Y Mills GB Ng KS Rao A Ryan M Wang J Weinstein JN Zhang J Abeshouse A Armenia J Chakravarty D Chatila WK de Bruijn I Gao J Gross BE Heins ZJ Kundra R la K Ladanyi M Luna A Nissan MG Ochoa A Phillips SM Reznik E Sanchez-Vega F Sander C Schultz N Sheridan R Sumer SO Sun Y Taylor BS Wang J Zhang H Anur P Peto M Spellman P Benz C Stuart JM Wong CK Yau C Hayes DN Parker JS Wilkerson MD Ally A Balasundaram M Bowlby R Brooks D Carlsen R Chuah E Dhalla N Holt R Jones SJM Kasaian K Lee D Ma Y Marra MA Mayo M Moore RA Mungall AJ Mungall K Robertson AG Sadeghi S Schein JE Sipahimalani P Tam A Thiessen N Tse K Wong T Berger AC Beroukhim R Cherniack AD Cibulskis C Gabriel SB Gao GF Ha G Meyerson M Schumacher SE Shih J Kucherlapati MH Kucherlapati RS Baylin S Cope L Danilova L Bootwalla MS Lai PH Maglinte DT van den Berg DJ Weisenberger DJ Auman JT Balu S Bodenheimer T Fan C Hoadley KA Hoyle AP Jefferys SR Jones CD Meng S Mieczkowski PA Mose LE Perou AH Perou CM Roach J Shi Y Simons JV Skelly T Soloway MG Tan D Veluvolu U Fan H Hinoue T Laird PW Shen H Zhou W Bellair M Chang K Covington K Creighton CJ Dinh H Doddapaneni HV Donehower LA Drummond J Gibbs RA Glenn R Hale W Han Y Hu J Korchina V Lee S Lewis L Li W Liu X Morgan M Morton D Muzny D Santibanez J Sheth M Shinbrot E Wang L Wang M Wheeler DA Xi L Zhao F Hess J Appelbaum EL Bailey M Cordes MG Ding L Fronick CC Fulton LA Fulton RS Kandoth C Mardis ER McLellan MD Miller CA Schmidt HK Wilson RK Crain D Curley E Gardner J Lau K Mallery D Morris S Paulauskis J Penny R Shelton C Shelton T Sherman M Thompson E Yena P Bowen J Gastier-Foster JM Gerken M Leraas KM Lichtenberg TM Ramirez NC Wise L Zmuda E Corcoran N Costello T Hovens C Carvalho AL de Carvalho AC Fregnani JH Longatto-Filho A Reis RM Scapulatempo-Neto C Silveira HCS Vidal DO Burnette A Eschbacher J Hermes B Noss A Singh R Anderson ML Castro PD Ittmann M Huntsman D Kohl B le X Thorp R Andry C Duffy ER Lyadov V Paklina O Setdikova G Shabunin A Tavobilov M McPherson C Warnick R Berkowitz R Cramer D Feltmate C Horowitz N Kibel A Muto M Raut CP Malykh A Barnholtz-Sloan JS Barrett W Devine K Fulop J Ostrom QT Shimmel K Wolinsky Y Sloan AE de Rose A Giuliante F Goodman M Karlan BY Hagedorn CH Eckman J Harr J Myers J Tucker K Zach LA Deyarmin B Hu H Kvecher L Larson C Mural RJ Somiari S Vicha A Zelinka T Bennett J Iacocca M Rabeno B Swanson P Latour M Lacombe L Têtu B Bergeron A McGraw M Staugaitis SM Chabot J Hibshoosh H Sepulveda A Su T Wang T Potapova O Voronina O Desjardins L Mariani O Roman-Roman S Sastre X Stern MH Cheng F Signoretti S Berchuck A Bigner D Lipp E Marks J McCall S McLendon R Secord A Sharp A Behera M Brat DJ Chen A Delman K Force S Khuri F Magliocca K Maithel S Olson JJ Owonikoko T Pickens A Ramalingam S Shin DM Sica G van Meir EG Zhang H Eijckenboom W Gillis A Korpershoek E Looijenga L Oosterhuis W Stoop H van Kessel KE Zwarthoff EC Calatozzolo C Cuppini L Cuzzubbo S DiMeco F Finocchiaro G Mattei L Perin A Pollo B Chen C Houck J Lohavanichbutr P Hartmann A Stoehr C Stoehr R Taubert H Wach S Wullich B Kycler W Murawa D Wiznerowicz M Chung K Edenfield WJ Martin J Baudin E Bubley G Bueno R de Rienzo A Richards WG Kalkanis S Mikkelsen T Noushmehr H Scarpace L Girard N Aymerich M Campo E Giné E Guillermo AL van Bang N Hanh PT Phu BD Tang Y Colman H Evason K Dottino PR Martignetti JA Gabra H Juhl H Akeredolu T Stepa S Hoon D Ahn K Kang KJ Beuschlein F Breggia A Birrer M Bell D Borad M Bryce AH Castle E Chandan V Cheville J Copland JA Farnell M Flotte T Giama N Ho T Kendrick M Kocher JP Kopp K Moser C Nagorney D O’Brien D O’Neill BP Patel T Petersen G Que F Rivera M Roberts L Smallridge R Smyrk T Stanton M Thompson RH Torbenson M Yang JD Zhang L Brimo F Ajani JA Gonzalez AMA Behrens C Bondaruk Broaddus R Czerniak B Esmaeli B Fujimoto J Gershenwald J Guo C Lazar AJ Logothetis C Meric-Bernstam F Moran C Ramondetta L Rice D Sood A Tamboli P Thompson T Troncoso P Tsao A Wistuba I Carter C Haydu L Hersey P Jakrot V Kakavand H Kefford R Lee K Long G Mann G Quinn M Saw R Scolyer R Shannon K Spillane A Stretch J Synott M Thompson J Wilmott J al-Ahmadie H Chan TA Ghossein R Gopalan A Levine DA Reuter V Singer S Singh B Tien NV Broudy T Mirsaidi C Nair P Drwiega P Miller J Smith J Zaren H Park JW Hung NP Kebebew E Linehan WM Metwalli AR Pacak K Pinto PA Schiffman M Schmidt LS Vocke CD Wentzensen N Worrell R Yang H Moncrieff M Goparaju C Melamed J Pass H Botnariuc N Caraman I Cernat M Chemencedji I Clipca A Doruc S Gorincioi G Mura S Pirtac M Stancul I Tcaciuc D Albert M Alexopoulou I Arnaout A Bartlett J Engel J Gilbert S Parfitt J Sekhon H Thomas G Rassl DM Rintoul RC Bifulco C Tamakawa R Urba W Hayward N Timmers H Antenucci A Facciolo F Grazi G Marino M Merola R de Krijger R Gimenez-Roqueplo AP Piché A Chevalier S McKercher G Birsoy K Barnett G Brewer C Farver C Naska T Pennell NA Raymond D Schilero C Smolenski K Williams F Morrison C Borgia JA Liptay MJ Pool M Seder CW Junker K Omberg L Dinkin M Manikhas G Alvaro D Bragazzi MC Cardinale V Carpino G Gaudio E Chesla D Cottingham S Dubina M Moiseenko F Dhanasekaran R Becker KF Janssen KP Slotta-Huspenina J Abdel-Rahman MH Aziz D Bell S Cebulla CM Davis A Duell R Elder JB Hilty J Kumar B Lang J Lehman NL Mandt R Nguyen P Pilarski R Rai K Schoenfield L Senecal K Wakely P Hansen P Lechan R Powers J Tischler A Grizzle WE Sexton KC Kastl A Henderson J Porten S Waldmann J Fassnacht M Asa SL Schadendorf D Couce M Graefen M Huland H Sauter G Schlomm T Simon R Tennstedt P Olabode O Nelson M Bathe O Carroll PR Chan JM Disaia P Glenn P Kelley RK Landen CN Phillips J Prados M Simko J Smith-McCune K VandenBerg S Roggin K Fehrenbach A Kendler A Sifri S Steele R Jimeno A Carey F Forgie I Mannelli M Carney M Hernandez B Campos B Herold-Mende C Jungk C Unterberg A von Deimling A Bossler A Galbraith J Jacobus L Knudson M Knutson T Ma D Milhem M Sigmund R Godwin AK Madan R Rosenthal HG Adebamowo C Adebamowo SN Boussioutas A Beer D Giordano T Mes-Masson AM Saad F Bocklage T Landrum L Mannel R Moore K Moxley K Postier R Walker J Zuna R Feldman M Valdivieso F Dhir R Luketich J Pinero EMM Quintero-Aguilo M Carlotti CG Jr Dos Santos JS Kemp R Sankarankuty A Tirapelli D Catto J Agnew K Swisher E Creaney J Robinson B Shelley CS Godwin EM Kendall S Shipman C Bradford C Carey T Haddad A Moyer J Peterson L Prince M Rozek L Wolf G Bowman R Fong KM Yang I Korst R Rathmell WK Fantacone-Campbell JL Hooke JA Kovatich AJ Shriver CD DiPersio J Drake B Govindan R Heath S Ley T van Tine B Westervelt P Rubin MA Lee JI Aredes ND Mariamidze A Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of Cancer Cell. 2018 173 2 291 304 10.1016/j.cell.2018.03.022 29625048
25. Ellrott K Bailey MH Saksena G Covington KR Kandoth C Stewart C Hess J Ma S Chiotti KE McLellan M Sofia HJ Hutter C Getz G Wheeler D Ding L Caesar-Johnson SJ Demchok JA Felau I Kasapi M Ferguson ML Hutter CM Sofia HJ Tarnuzzer R Wang Z Yang L Zenklusen JC Zhang J(J) Chudamani S Liu J Lolla L Naresh R Pihl T Sun Q Wan Y Wu Y Cho J DeFreitas T Frazer S Gehlenborg N Getz G Heiman DI Kim J Lawrence MS Lin P Meier S Noble MS Saksena G Voet D Zhang H Bernard B Chambwe N Dhankani V Knijnenburg T Kramer R Leinonen K Liu Y Miller M Reynolds S Shmulevich I Thorsson V Zhang W Akbani R Broom BM Hegde AM Ju Z Kanchi RS Korkut A Li J Liang H Ling S Liu W Lu Y Mills GB Ng KS Rao A Ryan M Wang J Weinstein JN Zhang J Abeshouse A Armenia J Chakravarty D Chatila WK de Bruijn I Gao J Gross BE Heins ZJ Kundra R la K Ladanyi M Luna A Nissan MG Ochoa A Phillips SM Reznik E Sanchez-Vega F Sander C Schultz N Sheridan R Sumer SO Sun Y Taylor BS Wang J Zhang H Anur P Peto M Spellman P Benz C Stuart JM Wong CK Yau C Hayes DN Parker Wilkerson MD Ally A Balasundaram M Bowlby R Brooks D Carlsen R Chuah E Dhalla N Holt R Jones SJM Kasaian K Lee D Ma Y Marra MA Mayo M Moore RA Mungall AJ Mungall K Robertson AG Sadeghi S Schein JE Sipahimalani P Tam A Thiessen N Tse K Wong T Berger AC Beroukhim R Cherniack AD Cibulskis C Gabriel SB Gao GF Ha G Meyerson M Schumacher SE Shih J Kucherlapati MH Kucherlapati RS Baylin S Cope L Danilova L Bootwalla MS Lai PH Maglinte DT van den Berg DJ Weisenberger DJ Auman JT Balu S Bodenheimer T Fan C Hoadley KA Hoyle AP Jefferys SR Jones CD Meng S Mieczkowski PA Mose LE Perou AH Perou CM Roach J Shi Y Simons JV Skelly T Soloway MG Tan D Veluvolu U Fan H Hinoue T Laird PW Shen H Zhou W Bellair M Chang K Covington K Creighton CJ Dinh H Doddapaneni HV Donehower LA Drummond J Gibbs RA Glenn R Hale W Han Y Hu J Korchina V Lee S Lewis L Li W Liu X Morgan M Morton D Muzny D Santibanez J Sheth M Shinbrot E Wang L Wang M Wheeler DA Xi L Zhao F Hess J Appelbaum EL Bailey M Cordes MG Ding L Fronick CC Fulton LA Fulton RS Kandoth C Mardis ER McLellan MD Miller CA Schmidt HK Wilson RK Crain D Curley E Gardner J Lau K Mallery D Morris S Paulauskis J Penny R Shelton C Shelton T Sherman M Thompson E Yena P Bowen J Gastier-Foster JM Gerken M Leraas KM Lichtenberg TM Ramirez NC Wise L Zmuda E Corcoran N Costello T Hovens C Carvalho AL de Carvalho AC Fregnani JH Longatto-Filho A Reis RM Scapulatempo-Neto C Silveira HCS Vidal DO Burnette A Eschbacher J Hermes B Noss A Singh R Anderson ML Castro PD Ittmann M Huntsman D Kohl B le X Thorp R Andry C Duffy ER Lyadov V Paklina O Setdikova G Shabunin A Tavobilov M McPherson C Warnick R Berkowitz R Cramer D Feltmate C Horowitz N Kibel A Muto M Raut CP Malykh A Barnholtz-Sloan JS Barrett W Devine K Fulop J Ostrom QT Shimmel K Wolinsky Y Sloan AE de Rose A Giuliante F Goodman M Karlan BY Hagedorn CH Eckman J Harr J Myers J Tucker K Zach LA Deyarmin B Hu H Kvecher L Larson C Mural RJ Somiari S Vicha A Zelinka T Bennett J Iacocca M Rabeno B Swanson P Latour M Lacombe L Têtu B Bergeron A McGraw M Staugaitis SM Chabot J Hibshoosh H Sepulveda A Su T Wang T Potapova O Voronina O Desjardins L Mariani O Roman-Roman S Sastre X Stern MH Cheng F Signoretti S Berchuck A Bigner D Lipp E Marks J McCall S McLendon R Secord A Sharp A Behera M Brat DJ Chen A Delman K Force S Khuri F Magliocca K Maithel S Olson JJ Owonikoko T Pickens A Ramalingam S Shin DM Sica G van Meir EG Zhang H Eijckenboom W Gillis A Korpershoek E Looijenga L Oosterhuis W Stoop H van Kessel KE Zwarthoff EC Calatozzolo C Cuppini L Cuzzubbo S DiMeco F Finocchiaro G Mattei L Perin A Pollo B Chen C Houck J Lohavanichbutr P Hartmann A Stoehr C Stoehr R Taubert H Wach S Wullich B Kycler W Murawa D Wiznerowicz M Chung K Edenfield WJ Martin J Baudin E Bubley G Bueno R de Rienzo A Richards WG Kalkanis S Mikkelsen T Noushmehr H Scarpace L Girard N Aymerich M Campo E Giné E Guillermo AL van Bang N Hanh PT Phu BD Tang Y Colman H Evason K Dottino PR Martignetti JA Gabra H Juhl H Akeredolu T Stepa S Hoon D Ahn K Kang KJ Beuschlein F Breggia A Birrer M Bell D Borad M Bryce AH Castle E Chandan V Cheville J Copland JA Farnell M Flotte T Giama N Ho T Kendrick M Kocher JP Kopp K Moser C Nagorney D O’Brien D O’Neill BP Patel T Petersen G Que F Rivera M Roberts L Smallridge R Smyrk T Stanton M Thompson RH Torbenson M Yang JD Zhang L Brimo F Ajani JA Angulo Gonzalez AM Behrens C Bondaruk J Broaddus R Czerniak B Esmaeli B Fujimoto J Gershenwald J Guo C Lazar AJ Logothetis C Meric-Bernstam F Moran C Ramondetta L Rice D Sood A Tamboli P Thompson T Troncoso P Tsao A Wistuba I Carter C Haydu L Hersey P Jakrot V Kakavand H Kefford R Lee K Long G Mann G Quinn M Saw R Scolyer R Shannon K Spillane A Stretch J Synott M Thompson J Wilmott J al-Ahmadie H Chan TA Ghossein R Gopalan A Levine DA Reuter V Singer S Singh B Tien NV Broudy T Mirsaidi C Nair P Drwiega P Miller J Smith J Zaren H Park JW Hung NP Kebebew E Linehan WM Metwalli AR Pacak K Pinto PA Schiffman M Schmidt LS Vocke CD Wentzensen N Worrell R Yang H Moncrieff M Goparaju C Melamed J Pass H Botnariuc N Caraman I Cernat M Chemencedji I Clipca A Doruc S Gorincioi G Mura S Pirtac M Stancul I Tcaciuc D Albert M Alexopoulou I Arnaout A Bartlett J Engel J Gilbert S Parfitt J Sekhon H Thomas G Rassl DM Rintoul RC Bifulco C Tamakawa R Urba W Hayward N Timmers H Antenucci A Facciolo F Grazi G Marino M Merola R de Krijger R Gimenez-Roqueplo AP Piché A Chevalier S McKercher G Birsoy K Barnett G Brewer C Farver C Naska T Pennell NA Raymond D Schilero C Smolenski K Williams F Morrison C Borgia JA Liptay MJ Pool M Seder CW Junker K Omberg L Dinkin M Manikhas G Alvaro D Bragazzi MC Cardinale V Carpino G Gaudio E Chesla D Cottingham S Dubina M Moiseenko F Dhanasekaran R Becker KF Janssen KP Slotta-Huspenina J Abdel-Rahman MH Aziz D Bell S Cebulla CM Davis A Duell R Elder JB Hilty J Kumar B Lang J Lehman NL Mandt R Nguyen P Pilarski R Rai K Schoenfield L Senecal K Wakely P Hansen P Lechan R Powers J Tischler A Grizzle WE Sexton KC Kastl A Henderson J Porten S Waldmann J Fassnacht M Asa SL Schadendorf D Couce M Graefen M Huland H Sauter G Schlomm T Simon R Tennstedt P Olabode O Nelson M Bathe O Carroll PR Chan JM Disaia P Glenn P Kelley RK Landen CN Phillips J Prados M Simko J Smith-McCune K VandenBerg S Roggin K Fehrenbach A Kendler A Sifri S Steele R Jimeno A Carey F Forgie I Mannelli M Carney M Hernandez B Campos B Herold-Mende C Jungk C Unterberg A von Deimling A Bossler A Galbraith J Jacobus L Knudson M Knutson T Ma D Milhem M Sigmund R Godwin AK Madan R Rosenthal HG Adebamowo C Adebamowo SN Boussioutas A Beer D Giordano T Mes-Masson AM Saad F Bocklage T Landrum L Mannel R Moore K Moxley K Postier R Walker J Zuna R Feldman M Valdivieso F Dhir R Luketich J Mora Pinero EM Quintero-Aguilo M Carlotti CG Jr Dos Santos JS Kemp R Sankarankuty A Tirapelli D Catto J Agnew K Swisher E Creaney J Robinson B Shelley CS Godwin EM Kendall S Shipman C Bradford C Carey T Haddad A Moyer J Peterson L Prince M Rozek L Wolf G Bowman R Fong KM Yang I Korst R Rathmell WK Fantacone-Campbell JL Hooke JA Kovatich AJ Shriver CD DiPersio J Drake B Govindan R Heath S Ley T van Tine B Westervelt P Rubin MA Lee JI Aredes ND Mariamidze A Scalable Open Science approach for mutation calling of tumor exomes using multiple genomic pipelines Cell Syst 2018 6 3 271 281 10.1016/j.cels.2018.03.002 29596782
26. Taylor AM Shih J Ha G Gao GF Zhang X Berger AC Schumacher SE Wang C Hu H Liu J Lazar AJ Cherniack AD Beroukhim R Meyerson M Caesar-Johnson SJ Demchok JA Felau I Kasapi M Ferguson ML Hutter CM Sofia HJ Tarnuzzer R Wang Z Yang L Zenklusen JC Zhang J(J) Chudamani S Liu J Lolla L Naresh R Pihl T Sun Q Wan Y Wu Y Cho J DeFreitas T Frazer S Gehlenborg N Getz G Heiman DI Kim J Lawrence MS Lin P Meier S Noble MS Saksena G Voet D Zhang H Bernard B Chambwe N Dhankani V Knijnenburg T Kramer R Leinonen K Liu Y Miller M Reynolds S Shmulevich I Thorsson V Zhang W Akbani R Broom BM Hegde AM Ju Z Kanchi RS Korkut A Li J Liang H Ling S Liu W Lu Y Mills GB Ng KS Rao A Ryan M Wang J Weinstein JN Zhang J Abeshouse A Armenia J Chakravarty D Chatila WK de Bruijn I Gao J Gross BE Heins ZJ Kundra R la K Ladanyi M Luna A Nissan MG Ochoa A Phillips SM Reznik E Sanchez-Vega F Sander C Schultz N Sheridan R Sumer SO Sun Y Taylor BS Wang J Zhang H Anur P Peto M Spellman P Benz C Stuart JM Wong CK Yau C Hayes DN Parker JS Wilkerson MD Ally A Balasundaram M Bowlby R Brooks D Carlsen R Chuah E Dhalla N Holt R Jones SJM Kasaian K Lee D Ma Y Marra MA Mayo M Moore RA Mungall AJ Mungall K Robertson AG Sadeghi S Schein JE Sipahimalani P Tam A Thiessen N Tse K Wong T Berger AC Beroukhim R Cherniack AD Cibulskis C Gabriel SB Gao GF Ha G Meyerson M Schumacher SE Shih J Kucherlapati MH Kucherlapati RS Baylin S Cope L Danilova L Bootwalla MS Lai PH Maglinte DT van den Berg DJ Weisenberger DJ Auman JT Balu S Bodenheimer T Fan C Hoadley KA Hoyle AP Jefferys SR Jones CD Meng S Mieczkowski PA Mose LE Perou AH Perou CM Roach J Shi Y Simons JV Skelly T Soloway MG Tan D Veluvolu U Fan H Hinoue T Laird PW Shen H Zhou W Bellair M Chang K Covington K Creighton CJ Dinh H Doddapaneni HV Donehower LA Drummond J Gibbs RA Glenn R Hale W Han Y Hu J Korchina V Lee S Lewis L Li W Liu X Morgan M Morton D Muzny D Santibanez J Sheth M Shinbrot E Wang L Wang M Wheeler DA Xi L Zhao F Hess J Appelbaum EL Bailey M Cordes MG Ding L Fronick CC Fulton LA Fulton RS Kandoth C Mardis ER McLellan MD Miller CA Schmidt HK Wilson RK Crain D Curley E Gardner J Lau K Mallery D Morris S Paulauskis J Penny R Shelton C Shelton T Sherman M Thompson E Yena P Bowen J Gastier-Foster JM Gerken M Leraas KM Lichtenberg TM Ramirez NC Wise L Zmuda E Corcoran N Costello T Hovens C Carvalho AL de Carvalho AC Fregnani JH Longatto-Filho A Reis RM Scapulatempo-Neto C Silveira HCS Vidal DO Burnette A Eschbacher J Hermes B Noss A Singh R Anderson ML Castro PD Ittmann M Huntsman D Kohl B le X Thorp R Andry C Duffy ER Lyadov V Paklina O Setdikova G Shabunin A Tavobilov M McPherson C Warnick R Berkowitz R Cramer D Feltmate C Horowitz N Kibel A Muto M Raut CP Malykh A Barnholtz-Sloan JS Barrett W Devine K Fulop J Ostrom QT Shimmel K Wolinsky Y Sloan AE de Rose A Giuliante F Goodman M Karlan BY Hagedorn CH Eckman J Harr J Myers J Tucker K Zach LA Deyarmin B Hu H Kvecher L Larson C Mural RJ Somiari S Vicha A Zelinka T Bennett J Iacocca M Rabeno B Swanson P Latour M Lacombe L Têtu B Bergeron A McGraw M Staugaitis SM Chabot J Hibshoosh H Sepulveda A Su T Wang T Potapova O Voronina O Desjardins L Mariani O Roman-Roman S Sastre X Stern MH Cheng F Signoretti S Berchuck A Bigner D Lipp E Marks J McCall S McLendon R Secord A Sharp A Behera M Brat DJ Chen A Delman K Force S Khuri F Magliocca K Maithel S Olson JJ Owonikoko T Pickens A Ramalingam S Shin DM Sica G van Meir EG Zhang H Eijckenboom W Gillis A Korpershoek E Looijenga L Oosterhuis W Stoop H van Kessel KE Zwarthoff EC Calatozzolo C Cuppini L Cuzzubbo S DiMeco F Finocchiaro G Mattei L Perin A Pollo B Chen C Houck J Lohavanichbutr P Hartmann A Stoehr C Stoehr R Taubert H Wach S Wullich B Kycler W Murawa D Wiznerowicz M Chung K Edenfield WJ Martin J Baudin E Bubley G Bueno R de Rienzo A Richards WG Kalkanis S Mikkelsen T Noushmehr H Scarpace L Girard N Aymerich M Campo E Giné E Guillermo AL van Bang N Hanh PT Phu BD Tang Y Colman H Evason K Dottino PR Martignetti JA Gabra H Juhl H Akeredolu T Stepa S Hoon D Ahn K Kang KJ Beuschlein F Breggia A Birrer M Bell D Borad M Bryce AH Castle E Chandan V Cheville J Copland JA Farnell M Flotte T Giama N Ho T Kendrick M Kocher JP Kopp K Moser C Nagorney D O’Brien D O’Neill BP Patel T Petersen G Que F Rivera M Roberts L Smallridge R Smyrk T Stanton M Thompson RH Torbenson M Yang JD Zhang L Brimo F Ajani JA Angulo Gonzalez AM Behrens C Bondaruk J Broaddus R Czerniak B Esmaeli B Fujimoto J Gershenwald J Guo C Lazar AJ Logothetis C Meric-Bernstam F Moran C Ramondetta L Rice D Sood A Tamboli P Thompson T Troncoso P Tsao A Wistuba I Carter C Haydu L Hersey P Jakrot V Kakavand H Kefford R Lee K Long G Mann G Quinn M Saw R Scolyer R Shannon K Spillane A Stretch J Synott M Thompson J Wilmott J al-Ahmadie H Chan TA Ghossein R Gopalan A Levine DA Reuter V Singer S Singh B Tien NV Broudy T Mirsaidi C Nair P Drwiega P Miller J Smith J Zaren H Park JW Hung NP Kebebew E Linehan WM Metwalli AR Pacak K Pinto PA Schiffman M Schmidt LS Vocke CD Wentzensen N Worrell R Yang H Moncrieff M Goparaju C Melamed J Pass H Botnariuc N Caraman I Cernat M Chemencedji I Clipca A Doruc S Gorincioi G Mura S Pirtac M Stancul I Tcaciuc D Albert M Alexopoulou I Arnaout A Bartlett J Engel J Gilbert S Parfitt J Sekhon H Thomas G Rassl DM Rintoul RC Bifulco C Tamakawa R Urba W Hayward N Timmers H Antenucci A Facciolo F Grazi G Marino M Merola R de Krijger R Gimenez-Roqueplo AP Piché A Chevalier S McKercher G Birsoy K Barnett G Brewer C Farver C Naska T Pennell NA Raymond D Schilero C Smolenski K Williams F Morrison C Borgia JA Liptay MJ Pool M Seder CW Junker K Omberg L Dinkin M Manikhas G Alvaro D Bragazzi MC Cardinale V Carpino G Gaudio E Chesla D Cottingham S Dubina M Moiseenko F Dhanasekaran R Becker KF Janssen KP Slotta-Huspenina J Abdel-Rahman MH Aziz D Bell S Cebulla CM Davis A Duell R Elder JB Hilty J Kumar B Lang J Lehman NL Mandt R Nguyen P Pilarski R Rai K Schoenfield L Senecal K Wakely P Hansen P Lechan R Powers J Tischler A Grizzle WE Sexton KC Kastl A Henderson J Porten S Waldmann J Fassnacht M Asa SL Schadendorf D Couce M Graefen M Huland H Sauter G Schlomm T Simon R Tennstedt P Olabode O Nelson M Bathe O Carroll PR Chan JM Disaia P Glenn P Kelley RK Landen CN Phillips J Prados M Simko J Smith-McCune K VandenBerg S Roggin K Fehrenbach A Kendler A Sifri S Steele R Jimeno A Carey F Forgie I Mannelli M Carney M Hernandez B Campos B Herold-Mende C Jungk C Unterberg A von Deimling A Bossler A Galbraith J Jacobus L Knudson M Knutson T Ma D Milhem M Sigmund R Godwin AK Madan R Rosenthal HG Adebamowo C Adebamowo SN Boussioutas A Beer D Giordano T Mes-Masson AM Saad F Bocklage T Landrum L Mannel R Moore K Moxley K Postier R Walker J Zuna R Feldman M Valdivieso F Dhir R Luketich J Mora Pinero EM Quintero-Aguilo M Carlotti CG Jr Dos Santos JS Kemp R Sankarankuty A Tirapelli D Catto J Agnew K Swisher E Creaney J Robinson B Shelley CS Godwin EM Kendall S Shipman C Bradford C Carey T Haddad A Moyer J Peterson L Prince M Rozek L Wolf G Bowman R Fong KM Yang I Korst R Rathmell WK Fantacone-Campbell JL Hooke JA Kovatich AJ Shriver CD DiPersio J Drake B Govindan R Heath S Ley T van Tine B Westervelt P Rubin MA Lee JI Aredes ND Mariamidze A Genomic and functional approaches to understanding Cancer aneuploidy Cancer Cell 2018 33 4 676 689 10.1016/j.ccell.2018.03.007 29622463
27. Gao Q Liang WW Foltz SM Mutharasu G Jayasinghe RG Cao S Liao WW Reynolds SM Wyczalkowski MA Yao L Yu L Sun SQ Chen K Lazar AJ Fields RC Wendl MC van Tine BA Vij R Chen F Nykter M Shmulevich I Ding L Caesar-Johnson SJ Demchok JA Felau I Kasapi M Ferguson ML Hutter CM Sofia HJ Tarnuzzer R Wang Z Yang L Zenklusen JC Zhang J(J) Chudamani S Liu J Lolla L Naresh R Pihl T Sun Q Wan Y Wu Y Cho J DeFreitas T Frazer S Gehlenborg N Getz G Heiman DI Kim J Lawrence MS Lin P Meier S Noble MS Saksena G Voet D Zhang H Bernard B Chambwe N Dhankani V Knijnenburg T Kramer R Leinonen K Liu Y Miller M Reynolds S Shmulevich I Thorsson V Zhang W Akbani R Broom BM Hegde AM Ju Z Kanchi RS Korkut A Li J Liang H Ling S Liu W Lu Y Mills GB Ng KS Rao A Ryan M Wang J Weinstein JN Zhang J Abeshouse A Armenia J Chakravarty D Chatila WK de Bruijn I Gao J Gross BE Heins ZJ Kundra R la K Ladanyi M Luna A Nissan MG Ochoa A Phillips SM Reznik E Sanchez-Vega F Sander C Schultz N Sheridan R Sumer SO Sun Y Taylor BS Wang J Zhang H Anur P Peto M Spellman P Benz C Stuart JM Wong CK Yau C Hayes DN Parker JS Wilkerson MD Ally A Balasundaram M Bowlby R Brooks D Carlsen R Chuah E Dhalla N Holt R Jones SJM Kasaian K Lee D Ma Y Marra MA Mayo M Moore RA Mungall AJ Mungall K Robertson AG Sadeghi S Schein JE Sipahimalani P Tam A Thiessen N Tse K Wong T Berger AC Beroukhim R Cherniack AD Cibulskis C Gabriel SB Gao GF Ha G Meyerson M Schumacher SE Shih J Kucherlapati MH Kucherlapati RS Baylin S Cope L Danilova L Bootwalla MS Lai PH Maglinte DT van den Berg DJ Weisenberger DJ Auman JT Balu S Bodenheimer T Fan C Hoadley KA Hoyle AP Jefferys SR Jones CD Meng S Mieczkowski PA Mose LE Perou AH Perou CM Roach J Shi Y Simons JV Skelly T Soloway MG Tan D Veluvolu U Fan H Hinoue T Laird PW Shen H Zhou W Bellair M Chang K Covington K Creighton CJ Dinh H Doddapaneni HV Donehower LA Drummond J Gibbs RA Glenn R Hale W Han Y Hu J Korchina V Lee S Lewis L Li W Liu X Morgan M Morton D Muzny D Santibanez J Sheth M Shinbrot E Wang L Wang M Wheeler DA Xi L Zhao F Hess J Appelbaum EL Bailey M Cordes MG Ding L Fronick CC Fulton LA Fulton RS Kandoth C Mardis ER McLellan MD Miller CA Schmidt HK Wilson RK Crain D Curley E Gardner J Lau K Mallery D Morris S Paulauskis J Penny R Shelton C Shelton T Sherman M Thompson E Yena P Bowen J Gastier-Foster JM Gerken M Leraas KM Lichtenberg TM Ramirez NC Wise L Zmuda E Corcoran N Costello T Hovens C Carvalho AL de Carvalho AC Fregnani JH Longatto-Filho A Reis RM Scapulatempo-Neto C Silveira HCS Vidal DO Burnette A Eschbacher J Hermes B Noss A Singh R Anderson ML Castro PD Ittmann M Huntsman D Kohl B le X Thorp R Andry C Duffy ER Lyadov V Paklina O Setdikova G Shabunin A Tavobilov M McPherson C Warnick R Berkowitz R Cramer D Feltmate C Horowitz N Kibel A Muto M Raut CP Malykh A Barnholtz-Sloan JS Barrett W Devine K Fulop J Ostrom QT Shimmel K Wolinsky Y Sloan AE de Rose A Giuliante F Goodman M Karlan BY Hagedorn CH Eckman J Harr J Myers J Tucker K Zach LA Deyarmin B Hu H Kvecher L Larson C Mural RJ Somiari S Vicha A Zelinka T Bennett J Iacocca M Rabeno B Swanson P Latour M Lacombe L Têtu B Bergeron A McGraw M Staugaitis SM Chabot J Hibshoosh H Sepulveda A Su T Wang T Potapova O Voronina O Desjardins L Mariani O Roman-Roman S Sastre X Stern MH Cheng F Signoretti S Berchuck A Bigner D Lipp E Marks J McCall S McLendon R Secord A Sharp A Behera M Brat DJ Chen A Delman K Force S Khuri F Magliocca K Maithel S Olson JJ Owonikoko T Pickens A Ramalingam S Shin DM Sica G van Meir EG Zhang H Eijckenboom W Gillis A Korpershoek E Looijenga L Oosterhuis W Stoop H van Kessel KE Zwarthoff EC Calatozzolo C Cuppini L Cuzzubbo S DiMeco F Finocchiaro G Mattei L Perin A Pollo B Chen C Houck J Lohavanichbutr P Hartmann A Stoehr C Stoehr R Taubert H Wach S Wullich B Kycler W Murawa D Wiznerowicz M Chung K Edenfield WJ Martin J Baudin E Bubley G Bueno R de Rienzo A Richards WG Kalkanis S Mikkelsen T Noushmehr H Scarpace L Girard N Aymerich M Campo E Giné E Guillermo AL van Bang N Hanh PT Phu BD Tang Y Colman H Evason K Dottino PR Martignetti JA Gabra H Juhl H Akeredolu T Stepa S Hoon D Ahn K Kang KJ Beuschlein F Breggia A Birrer M Bell D Borad M Bryce AH Castle E Chandan V Cheville J Copland JA Farnell M Flotte T Giama N Ho T Kendrick M Kocher JP Kopp K Moser C Nagorney D O’Brien D O’Neill BP Patel T Petersen G Que F Rivera M Roberts L Smallridge R Smyrk T Stanton M Thompson RH Torbenson M Yang JD Zhang L Brimo F Ajani JA Gonzalez AMA Behrens C Bondaruk J Broaddus R Czerniak B Esmaeli B Fujimoto J Gershenwald J Guo C Lazar AJ Logothetis C Meric-Bernstam F Moran C Ramondetta L Rice D Sood A Tamboli P Thompson T Troncoso P Tsao A Wistuba I Carter C Haydu L Hersey P Jakrot V Kakavand H Kefford R Lee K Long G Mann G Quinn M Saw R Scolyer R Shannon K Spillane A Stretch J Synott M Thompson J Wilmott J al-Ahmadie H Chan TA Ghossein R Gopalan A Levine DA Reuter V Singer S Singh B Tien NV Broudy T Mirsaidi C Nair P Drwiega P Miller J Smith J Zaren H Park JW Hung NP Kebebew E Linehan WM Metwalli AR Pacak K Pinto PA Schiffman M Schmidt LS Vocke CD Wentzensen N Worrell R Yang H Moncrieff M Goparaju C Melamed J Pass H Botnariuc N Caraman I Cernat M Chemencedji I Clipca A Doruc S Gorincioi G Mura S Pirtac M Stancul I Tcaciuc D Albert M Alexopoulou I Arnaout A Bartlett J Engel J Gilbert S Parfitt J Sekhon H Thomas G Rassl DM Rintoul RC Bifulco C Tamakawa R Urba W Hayward N Timmers H Antenucci A Facciolo F Grazi G Marino M Merola R de Krijger R Gimenez-Roqueplo AP Piché A Chevalier S McKercher G Birsoy K Barnett G Brewer C Farver C Naska T Pennell NA Raymond D Schilero C Smolenski K Williams F Morrison C Borgia JA Liptay MJ Pool M Seder CW Junker K Omberg L Dinkin M Manikhas G Alvaro D Bragazzi MC Cardinale V Carpino G Gaudio E Chesla D Cottingham S Dubina M Moiseenko F Dhanasekaran R Becker KF Janssen KP Slotta-Huspenina J Abdel-Rahman MH Aziz D Bell S Cebulla CM Davis A Duell R Elder JB Hilty J Kumar B Lang J Lehman NL Mandt R Nguyen P Pilarski R Rai K Schoenfield L Senecal K Wakely P Hansen P Lechan R Powers J Tischler A Grizzle WE Sexton KC Kastl A Henderson J Porten S Waldmann J Fassnacht M Asa SL Schadendorf D Couce M Graefen M Huland H Sauter G Schlomm T Simon R Tennstedt P Olabode O Nelson M Bathe O Carroll PR Chan JM Disaia P Glenn P Kelley RK Landen CN Phillips J Prados M Simko J Smith-McCune K VandenBerg S Roggin K Fehrenbach A Kendler A Sifri S Steele R Jimeno A Carey F Forgie I Mannelli M Carney M Hernandez B Campos B Herold-Mende C Jungk C Unterberg A von Deimling A Bossler A Galbraith J Jacobus L Knudson M Knutson T Ma D Milhem M Sigmund R Godwin AK Madan R Rosenthal HG Adebamowo C Adebamowo SN Boussioutas A Beer D Giordano T Mes-Masson AM Saad F Bocklage T Landrum L Mannel R Moore K Moxley K Postier R Walker J Zuna R Feldman M Valdivieso F Dhir R Luketich J Pinero EMM Quintero-Aguilo M Carlotti CG Jr Dos Santos JS Kemp R Sankarankuty A Tirapelli D Catto J Agnew K Swisher E Creaney J Robinson B Shelley CS Godwin EM Kendall S Shipman C Bradford C Carey T Haddad A Moyer J Peterson L Prince M Rozek L Wolf G Bowman R Fong KM Yang I Korst R Rathmell WK Fantacone-Campbell JL Hooke JA Kovatich AJ Shriver CD DiPersio J Drake B Govindan R Heath S Ley T van Tine B Westervelt P Rubin MA Lee JI Aredes ND Mariamidze A Driver fusions and their implications in the development and treatment of human cancers Cell Rep 2018 23 1 227 238 10.1016/j.celrep.2018.03.050 29617662
28. Liu J Lichtenberg T Hoadley KA Poisson LM Lazar AJ Cherniack AD An integrated TCGA pan-Cancer clinical data resource to drive high-quality survival outcome analytics Cell. 2018 173 2 400 416 10.1016/j.cell.2018.02.052 29625055
29. Sanchez-Vega F Mina M Armenia J Chatila WK Luna A La KC Oncogenic signaling pathways in the Cancer genome atlas Cell. 2018 173 2 321 337 10.1016/j.cell.2018.03.035 29625050
30. Jonsson P Lin AL Young RJ DiStefano NM Hyman DM Li BT Genomic correlates of disease progression and treatment response in prospectively characterized gliomas Clin Cancer Res 2019 25 18 5537 5547 10.1158/1078-0432.CCR-19-0032 31263031
31. Johnson BE Mazor T Hong C Barnes M Aihara K McLean CY Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma Science. 2014 343 6167 189 193 10.1126/science.1239947 24336570
32. Ceccarelli M Barthel FP Malta TM Sabedot TS Salama SR Murray BA Morozova O Newton Y Radenbaugh A Pagnotta SM Anjum S Wang J Manyam G Zoppoli P Ling S Rao AA Grifford M Cherniack AD Zhang H Poisson L Carlotti CG Jr Tirapelli DPC Rao A Mikkelsen T Lau CC Yung WKA Rabadan R Huse J Brat DJ Lehman NL Barnholtz-Sloan JS Zheng S Hess K Rao G Meyerson M Beroukhim R Cooper L Akbani R Wrensch M Haussler D Aldape KD Laird PW Gutmann DH Noushmehr H Iavarone A Verhaak RGW Anjum S Arachchi H Auman JT Balasundaram M Balu S Barnett G Baylin S Bell S Benz C Bir N Black KL Bodenheimer T Boice L Bootwalla MS Bowen J Bristow CA Butterfield YSN Chen QR Chin L Cho J Chuah E Chudamani S Coetzee SG Cohen ML Colman H Couce M D’Angelo F Davidsen T Davis A Demchok JA Devine K Ding L Duell R Elder JB Eschbacher JM Fehrenbach A Ferguson M Frazer S Fuller G Fulop J Gabriel SB Garofano L Gastier-Foster JM Gehlenborg N Gerken M Getz G Giannini C Gibson WJ Hadjipanayis A Hayes DN Heiman DI Hermes B Hilty J Hoadley KA Hoyle AP Huang M Jefferys SR Jones CD Jones SJM Ju Z Kastl A Kendler A Kim J Kucherlapati R Lai PH Lawrence MS Lee S Leraas KM Lichtenberg TM Lin P Liu Y Liu J Ljubimova JY Lu Y Ma Y Maglinte DT Mahadeshwar HS Marra MA McGraw M McPherson C Meng S Mieczkowski PA Miller CR Mills GB Moore RA Mose LE Mungall AJ Naresh R Naska T Neder L Noble MS Noss A O’Neill BP Ostrom QT Palmer C Pantazi A Parfenov M Park PJ Parker JS Perou CM Pierson CR Pihl T Protopopov A Radenbaugh A Ramirez NC Rathmell WK Ren X Roach J Robertson AG Saksena G Schein JE Schumacher SE Seidman J Senecal K Seth S Shen H Shi Y Shih J Shimmel K Sicotte H Sifri S Silva T Simons JV Singh R Skelly T Sloan AE Sofia HJ Soloway MG Song X Sougnez C Souza C Staugaitis SM Sun H Sun C Tan D Tang J Tang Y Thorne L Trevisan FA Triche T van den Berg DJ Veluvolu U Voet D Wan Y Wang Z Warnick R Weinstein JN Weisenberger DJ Wilkerson MD Williams F Wise L Wolinsky Y Wu J Xu AW Yang L Yang L Zack TI Zenklusen JC Zhang J Zhang W Zhang J Zmuda E Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma Cell. 2016 164 3 550 563 10.1016/j.cell.2015.12.028 26824661
33. Zhao J Chen AX Gartrell RD Silverman AM Aparicio L Chu T Bordbar D Shan D Samanamud J Mahajan A Filip I Orenbuch R Goetz M Yamaguchi JT Cloney M Horbinski C Lukas RV Raizer J Rae AI Yuan J Canoll P Bruce JN Saenger YM Sims P Iwamoto FM Sonabend AM Rabadan R Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma Nat Med 2019 25 3 462 469 10.1038/s41591-019-0349-y 30742119
34. Brennan CW Verhaak RG McKenna A Campos B Noushmehr H Salama SR The somatic genomic landscape of glioblastoma Cell. 2013 155 2 462 477 10.1016/j.cell.2013.09.034 24120142
35. Cancer Genome Atlas Research N Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature. 2008 455 7216 1061 1068 10.1038/nature07385 18772890
36. Bhandari V Hoey C Liu LY Lalonde E Ray J Livingstone J Lesurf R Shiah YJ Vujcic T Huang X Espiritu SMG Heisler LE Yousif F Huang V Yamaguchi TN Yao CQ Sabelnykova VY Fraser M Chua MLK van der Kwast T Liu SK Boutros PC Bristow RG Molecular landmarks of tumor hypoxia across cancer types Nat Genet 2019 51 2 308 318 10.1038/s41588-018-0318-2 30643250
37. Thomas AA Abrey LE Terziev R Raizer J Martinez NL Forsyth P Paleologos N Matasar M Sauter CS Moskowitz C Nimer SD DeAngelis LM Kaley T Grimm S Louis DN Cairncross JG Panageas KS Briggs S Faivre G Mohile NA Mehta J Jonsson P Chakravarty D Gao J Schultz N Brennan CW Huse JT Omuro A Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma Neuro-Oncology 2017 19 10 1380 1390 10.1093/neuonc/nox086 28472509
38. Pugh TJ Weeraratne SD Archer TC Pomeranz Krummel DA Auclair D Bochicchio J Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations Nature. 2012 488 7409 106 110 10.1038/nature11329 22820256
39. Jones DT Jager N Kool M Zichner T Hutter B Sultan M Dissecting the genomic complexity underlying medulloblastoma Nature. 2012 488 7409 100 105 10.1038/nature11284 22832583
40. Robinson G Parker M Kranenburg TA Lu C Chen X Ding L Phoenix TN Hedlund E Wei L Zhu X Chalhoub N Baker SJ Huether R Kriwacki R Curley N Thiruvenkatam R Wang J Wu G Rusch M Hong X Becksfort J Gupta P Ma J Easton J Vadodaria B Onar-Thomas A Lin T Li S Pounds S Paugh S Zhao D Kawauchi D Roussel MF Finkelstein D Ellison DW Lau CC Bouffet E Hassall T Gururangan S Cohn R Fulton RS Fulton LL Dooling DJ Ochoa K Gajjar A Mardis ER Wilson RK Downing JR Zhang J Gilbertson RJ Novel mutations target distinct subgroups of medulloblastoma Nature. 2012 488 7409 43 48 10.1038/nature11213 22722829
41. Morrissy AS Garzia L Shih DJ Zuyderduyn S Huang X Skowron P Divergent clonal selection dominates medulloblastoma at recurrence Nature. 2016 529 7586 351 357 10.1038/nature16478 26760213
42. Jones DT Hutter B Jager N Korshunov A Kool M Warnatz HJ Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma Nat Genet 2013 45 8 927 932 10.1038/ng.2682 23817572
43. Fishbein L Leshchiner I Walter V Danilova L Robertson AG Johnson AR Lichtenberg TM Murray BA Ghayee HK Else T Ling S Jefferys SR de Cubas AA Wenz B Korpershoek E Amelio AL Makowski L Rathmell WK Gimenez-Roqueplo AP Giordano TJ Asa SL Tischler AS Pacak K Nathanson KL Wilkerson MD Akbani R Ally A Amar L Amelio AL Arachchi H Asa SL Auchus RJ Auman JT Baertsch R Balasundaram M Balu S Bartsch DK Baudin E Bauer T Beaver A Benz C Beroukhim R Beuschlein F Bodenheimer T Boice L Bowen J Bowlby R Brooks D Carlsen R Carter S Cassol CA Cherniack AD Chin L Cho J Chuah E Chudamani S Cope L Crain D Curley E Danilova L de Cubas AA de Krijger RR Demchok JA Deutschbein T Dhalla N Dimmock D Dinjens WNM Else T Eng C Eschbacher J Fassnacht M Felau I Feldman M Ferguson ML Fiddes I Fishbein L Frazer S Gabriel SB Gardner J Gastier-Foster JM Gehlenborg N Gerken M Getz G Geurts J Ghayee HK Gimenez-Roqueplo AP Giordano TJ Goldman M Graim K Gupta M Haan D Hahner S Hantel C Haussler D Hayes DN Heiman DI Hoadley KA Holt RA Hoyle AP Huang M Hunt B Hutter CM Jefferys SR Johnson AR Jones SJM Jones CD Kasaian K Kebebew E Kim J Kimes P Knijnenburg T Korpershoek E Lander E Lawrence MS Lechan R Lee D Leraas KM Lerario A Leshchiner I Lichtenberg TM Lin P Ling S Liu J LiVolsi VA Lolla L Lotan Y Lu Y Ma Y Maison N Makowski L Mallery D Mannelli M Marquard J Marra MA Matthew T Mayo M Méatchi T Meng S Merino MJ Mete O Meyerson M Mieczkowski PA Mills GB Moore RA Morozova O Morris S Mose LE Mungall AJ Murray BA Naresh R Nathanson KL Newton Y Ng S Ni Y Noble MS Nwariaku F Pacak K Parker JS Paul E Penny R Perou CM Perou AH Pihl T Powers J Rabaglia J Radenbaugh A Ramirez NC Rao A Rathmell WK Riester A Roach J Robertson AG Sadeghi S Saksena G Salama S Saller C Sandusky G Sbiera S Schein JE Schumacher SE Shelton C Shelton T Sheth M Shi Y Shih J Shmulevich I Simons JV Sipahimalani P Skelly T Sofia HJ Sokolov A Soloway MG Sougnez C Stuart J Sun C Swatloski T Tam A Tan D Tarnuzzer R Tarvin K Thiessen N Thorne LB Timmers HJ Tischler AS Tse K Uzunangelov V van Berkel A Veluvolu U Vicha A Voet D Waldmann J Walter V Wan Y Wang Z Wang TS Weaver J Weinstein JN Weismann D Wenz B Wilkerson MD Wise L Wong T Wong C Wu Y Yang L Zelinka T Zenklusen JC Zhang J(J) Zhang W Zhu J Zinzindohoué F Zmuda E Comprehensive molecular characterization of Pheochromocytoma and Paraganglioma Cancer Cell 2017 31 2 181 193 10.1016/j.ccell.2017.01.001 28162975
44. Dahiya S Emnett RJ Haydon DH Leonard JR Phillips JJ Perry A Gutmann DH BRAF-V600E mutation in pediatric and adult glioblastoma Neuro-Oncology 2014 16 2 318 319 10.1093/neuonc/not146 24311634
45. Rodin SN Rodin AS Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells Proc Natl Acad Sci U S A 1998 95 20 11927 11932 10.1073/pnas.95.20.11927 9751767
46. Lai A Kharbanda S Pope WB Tran A Solis OE Peale F Forrest WF Pujara K Carrillo JA Pandita A Ellingson BM Bowers CW Soriano RH Schmidt NO Mohan S Yong WH Seshagiri S Modrusan Z Jiang Z Aldape KD Mischel PS Liau LM Escovedo CJ Chen W Nghiemphu PL James CD Prados MD Westphal M Lamszus K Cloughesy T Phillips HS Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin J Clin Oncol 2011 29 34 4482 4490 10.1200/JCO.2010.33.8715 22025148
47. Dunn GP Andronesi OC Cahill DP From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma Neurosurg Focus 2013 34 2 E2 10.3171/2012.12.FOCUS12355 23373447
48. Liu XY Gerges N Korshunov A Sabha N Khuong-Quang DA Fontebasso AM Fleming A Hadjadj D Schwartzentruber J Majewski J Dong Z Siegel P Albrecht S Croul S Jones DTW Kool M Tonjes M Reifenberger G Faury D Zadeh G Pfister S Jabado N Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations Acta Neuropathol 2012 124 5 615 625 10.1007/s00401-012-1031-3 22886134
49. Cai J Zhang C Zhang W Wang G Yao K Wang Z Li G Qian Z Li Y Jiang T Jiang C ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors Oncoscience. 2016 3 7–8 258 265 10.18632/oncoscience.317 27713914
50. Modrek AS Golub D Khan T Bready D Prado J Bowman C Deng J Zhang G Rocha PP Raviram R Lazaris C Stafford JM LeRoy G Kader M Dhaliwal J Bayin NS Frenster JD Serrano J Chiriboga L Baitalmal R Nanjangud G Chi AS Golfinos JG Wang J Karajannis MA Bonneau RA Reinberg D Tsirigos A Zagzag D Snuderl M Skok JA Neubert TA Placantonakis DG Low-grade astrocytoma mutations in IDH1, P53, and ATRX cooperate to block differentiation of human neural stem cells via repression of SOX2 Cell Rep 2017 21 5 1267 1280 10.1016/j.celrep.2017.10.009 29091765
51. Kannan K Inagaki A Silber J Gorovets D Zhang J Kastenhuber ER Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma Oncotarget. 2012 3 10 1194 1203 10.18632/oncotarget.689 23104868
52. Weber CK Slupsky JR Kalmes HA Rapp UR Active Ras induces heterodimerization of cRaf and BRaf Cancer Res 2001 61 9 3595 3598 11325826
53. Mizutani S Inouye K Koide H Kaziro Y Involvement of B-Raf in Ras-induced Raf-1 activation FEBS Lett 2001 507 3 295 298 10.1016/S0014-5793(01)02992-1 11696358
54. Wang HG Rapp UR Reed JC Bcl-2 targets the protein kinase Raf-1 to mitochondria Cell. 1996 87 4 629 638 10.1016/S0092-8674(00)81383-5 8929532
55. Wang HG Takayama S Rapp UR Reed JC Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1 Proc Natl Acad Sci U S A 1996 93 14 7063 7068 10.1073/pnas.93.14.7063 8692945
56. Hemann MT Lowe SW The p53-Bcl-2 connection Cell Death Differ 2006 13 8 1256 1259 10.1038/sj.cdd.4401962 16710363
57. Ryall S Tabori U Hawkins C A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment Brain Tumor Pathol 2017 34 2 1 11 10.1007/s10014-017-0282-z 28116538
58. Lassaletta A Zapotocky M Mistry M Ramaswamy V Tabori U Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas J Clin Oncol 2017 35 25 JCO2016718726 10.1200/JCO.2016.71.8726
59. Schiffman JD Hodgson JG VandenBerg SR Flaherty P Polley MY Yu M Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas Cancer Res 2010 70 2 512 519 10.1158/0008-5472.CAN-09-1851 20068183
60. Mistry M Zhukova N Merico D Rakopoulos P Krishnatry R Shago M Stavropoulos J Alon N Pole JD Ray PN Navickiene V Mangerel J Remke M Buczkowicz P Ramaswamy V Guerreiro Stucklin A Li M Young EJ Zhang C Castelo-Branco P Bakry D Laughlin S Shlien A Chan J Ligon KL Rutka JT Dirks PB Taylor MD Greenberg M Malkin D Huang A Bouffet E Hawkins CE Tabori U BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma J Clin Oncol 2015 33 9 1015 1022 10.1200/JCO.2014.58.3922 25667294
61. Robinson JP VanBrocklin MW Guilbeault AR Signorelli DL Brandner S Holmen SL Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation Oncogene. 2010 29 3 335 344 10.1038/onc.2009.333 19855433
62. Putlyaeva LV Demin DE Uvarova AN Zinevich LS Prokofjeva MM Gazizova GR Shagimardanova EI Schwartz AM PTPN11 knockdown prevents changes in the expression of genes controlling cell cycle, chemotherapy resistance, and oncogene-induced senescence in human thyroid cells overexpressing BRAF V600E oncogenic protein Biochemistry (Mosc) 2020 85 1 108 118 10.1134/S0006297920010101 32079522
63. Louis DN Perry A Reifenberger G von Deimling A Figarella-Branger D Cavenee WK Ohgaki H Wiestler OD Kleihues P Ellison DW The 2016 World Health Organization classification of tumors of the central nervous system: a summary Acta Neuropathol 2016 131 6 803 820 10.1007/s00401-016-1545-1 27157931
64. Wellbrock C Karasarides M Marais R The RAF proteins take Centre stage Nat Rev Mol Cell Biol 2004 5 11 875 885 10.1038/nrm1498 15520807

